Cargando…

Jinhua Qinggan granules attenuates acute lung injury by promotion of neutrophil apoptosis and inhibition of TLR4/MyD88/NF-κB pathway

ETHNOPHARMACOLOGICAL RELEVANCE: Acute lung injury (ALI) is one of the fatal complications of respiratory virus infections such as influenza virus and coronavirus, which has high clinical morbidity and mortality. Jinhua Qinggan granules (JHQG) has been approved by China Food and Drug Administration i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yanhui, Han, Qianqian, Wang, Lei, Wang, Baiyan, Chen, Jianshuang, Cai, Bangrong, Wu, Can, Zhu, Xiali, Liu, Fugang, Han, Deen, Dong, Haoran, Jia, Yongyan, Liu, Yalin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523948/
https://www.ncbi.nlm.nih.gov/pubmed/36183949
http://dx.doi.org/10.1016/j.jep.2022.115763
_version_ 1784800401252417536
author Zhu, Yanhui
Han, Qianqian
Wang, Lei
Wang, Baiyan
Chen, Jianshuang
Cai, Bangrong
Wu, Can
Zhu, Xiali
Liu, Fugang
Han, Deen
Dong, Haoran
Jia, Yongyan
Liu, Yalin
author_facet Zhu, Yanhui
Han, Qianqian
Wang, Lei
Wang, Baiyan
Chen, Jianshuang
Cai, Bangrong
Wu, Can
Zhu, Xiali
Liu, Fugang
Han, Deen
Dong, Haoran
Jia, Yongyan
Liu, Yalin
author_sort Zhu, Yanhui
collection PubMed
description ETHNOPHARMACOLOGICAL RELEVANCE: Acute lung injury (ALI) is one of the fatal complications of respiratory virus infections such as influenza virus and coronavirus, which has high clinical morbidity and mortality. Jinhua Qinggan granules (JHQG) has been approved by China Food and Drug Administration in the treatment of H1N1 influenza and mild or moderate novel coronavirus disease 2019 (COVID-19), which is an herbal formula developed based on Maxingshigan decoction and Yinqiao powder that have been used to respiratory diseases in China for thousands of years. However, the underlying mechanism of JHQG in treating infectious diseases remains unclear. AIM OF THE STUDY: This study investigated the effects of JHQG on neutrophil apoptosis and key signaling pathways in lipopolysaccharide (LPS) -induced ALI mice in order to explore its mechanism of anti-inflammation. MATERIALS AND METHODS: The effect of JHQG on survival rate was observed in septic mouse model by intraperitoneal injection of LPS (20 mg/kg). To better pharmacological evaluation, the mice received an intratracheal injection of 5 mg/kg LPS. Lung histopathological changes, wet-to-dry ratio of the lungs, and MPO activity in the lungs and total protein concentration, total cells number, TNF-α, IL-1β, IL-6, and MIP-2 levels in BALF were assessed. Neutrophil apoptosis rate was detected by Ly6G-APC/Annexin V-FITC staining. Key proteins associated with apoptosis including caspase 3/7 activity, Bcl-xL and Mcl-1 were measured by flow cytometry and confocal microscope, respectively. TLR4 receptor and its downstream signaling were analyzed by Western blot assay and immunofluorescence, respectively. RESULTS: JHQG treatment at either 6 or 12 g/kg/day resulted in 20% increase of survival in 20 mg/kg LPS-induced mice. In the model of 5 mg/kg LPS-induced mice, JHQG obviously decreased the total protein concentration in BALF, wet-to-dry ratio of the lungs, and lung histological damage. It also attenuated the MPO activity and the proportion of Ly6G staining positive neutrophils in the lungs, as well as the MIP-2 levels in BALF were reduced. JHQG inhibited the expression of Mcl-1 and Bcl-xL and enhanced caspase-3/7 activity, indicating that JHQG partially acted in promoting neutrophil apoptosis via intrinsic mitochondrial apoptotic pathway. The levels of TNF-α, IL-1β, and IL-6 were significantly declined in LPS-induced mice treated with JHQG. Furthermore, JHQG reduced the protein expression of TLR4, MyD88, p-p65 and the proportion of nuclei p65, suggesting that JHQG treatment inhibited TLR4/MyD88/NF-κB pathway. CONCLUSION: JHQG reduced pulmonary inflammation and protected mice from LPS-induced ALI by promoting neutrophil apoptosis and inhibition of TLR4/MyD88/NF-κB pathway, suggesting that JHQG may be a promising drug for treatment of ALI.
format Online
Article
Text
id pubmed-9523948
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Authors. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-95239482022-09-30 Jinhua Qinggan granules attenuates acute lung injury by promotion of neutrophil apoptosis and inhibition of TLR4/MyD88/NF-κB pathway Zhu, Yanhui Han, Qianqian Wang, Lei Wang, Baiyan Chen, Jianshuang Cai, Bangrong Wu, Can Zhu, Xiali Liu, Fugang Han, Deen Dong, Haoran Jia, Yongyan Liu, Yalin J Ethnopharmacol Article ETHNOPHARMACOLOGICAL RELEVANCE: Acute lung injury (ALI) is one of the fatal complications of respiratory virus infections such as influenza virus and coronavirus, which has high clinical morbidity and mortality. Jinhua Qinggan granules (JHQG) has been approved by China Food and Drug Administration in the treatment of H1N1 influenza and mild or moderate novel coronavirus disease 2019 (COVID-19), which is an herbal formula developed based on Maxingshigan decoction and Yinqiao powder that have been used to respiratory diseases in China for thousands of years. However, the underlying mechanism of JHQG in treating infectious diseases remains unclear. AIM OF THE STUDY: This study investigated the effects of JHQG on neutrophil apoptosis and key signaling pathways in lipopolysaccharide (LPS) -induced ALI mice in order to explore its mechanism of anti-inflammation. MATERIALS AND METHODS: The effect of JHQG on survival rate was observed in septic mouse model by intraperitoneal injection of LPS (20 mg/kg). To better pharmacological evaluation, the mice received an intratracheal injection of 5 mg/kg LPS. Lung histopathological changes, wet-to-dry ratio of the lungs, and MPO activity in the lungs and total protein concentration, total cells number, TNF-α, IL-1β, IL-6, and MIP-2 levels in BALF were assessed. Neutrophil apoptosis rate was detected by Ly6G-APC/Annexin V-FITC staining. Key proteins associated with apoptosis including caspase 3/7 activity, Bcl-xL and Mcl-1 were measured by flow cytometry and confocal microscope, respectively. TLR4 receptor and its downstream signaling were analyzed by Western blot assay and immunofluorescence, respectively. RESULTS: JHQG treatment at either 6 or 12 g/kg/day resulted in 20% increase of survival in 20 mg/kg LPS-induced mice. In the model of 5 mg/kg LPS-induced mice, JHQG obviously decreased the total protein concentration in BALF, wet-to-dry ratio of the lungs, and lung histological damage. It also attenuated the MPO activity and the proportion of Ly6G staining positive neutrophils in the lungs, as well as the MIP-2 levels in BALF were reduced. JHQG inhibited the expression of Mcl-1 and Bcl-xL and enhanced caspase-3/7 activity, indicating that JHQG partially acted in promoting neutrophil apoptosis via intrinsic mitochondrial apoptotic pathway. The levels of TNF-α, IL-1β, and IL-6 were significantly declined in LPS-induced mice treated with JHQG. Furthermore, JHQG reduced the protein expression of TLR4, MyD88, p-p65 and the proportion of nuclei p65, suggesting that JHQG treatment inhibited TLR4/MyD88/NF-κB pathway. CONCLUSION: JHQG reduced pulmonary inflammation and protected mice from LPS-induced ALI by promoting neutrophil apoptosis and inhibition of TLR4/MyD88/NF-κB pathway, suggesting that JHQG may be a promising drug for treatment of ALI. The Authors. Published by Elsevier B.V. 2023-01-30 2022-09-29 /pmc/articles/PMC9523948/ /pubmed/36183949 http://dx.doi.org/10.1016/j.jep.2022.115763 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Zhu, Yanhui
Han, Qianqian
Wang, Lei
Wang, Baiyan
Chen, Jianshuang
Cai, Bangrong
Wu, Can
Zhu, Xiali
Liu, Fugang
Han, Deen
Dong, Haoran
Jia, Yongyan
Liu, Yalin
Jinhua Qinggan granules attenuates acute lung injury by promotion of neutrophil apoptosis and inhibition of TLR4/MyD88/NF-κB pathway
title Jinhua Qinggan granules attenuates acute lung injury by promotion of neutrophil apoptosis and inhibition of TLR4/MyD88/NF-κB pathway
title_full Jinhua Qinggan granules attenuates acute lung injury by promotion of neutrophil apoptosis and inhibition of TLR4/MyD88/NF-κB pathway
title_fullStr Jinhua Qinggan granules attenuates acute lung injury by promotion of neutrophil apoptosis and inhibition of TLR4/MyD88/NF-κB pathway
title_full_unstemmed Jinhua Qinggan granules attenuates acute lung injury by promotion of neutrophil apoptosis and inhibition of TLR4/MyD88/NF-κB pathway
title_short Jinhua Qinggan granules attenuates acute lung injury by promotion of neutrophil apoptosis and inhibition of TLR4/MyD88/NF-κB pathway
title_sort jinhua qinggan granules attenuates acute lung injury by promotion of neutrophil apoptosis and inhibition of tlr4/myd88/nf-κb pathway
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523948/
https://www.ncbi.nlm.nih.gov/pubmed/36183949
http://dx.doi.org/10.1016/j.jep.2022.115763
work_keys_str_mv AT zhuyanhui jinhuaqinggangranulesattenuatesacutelunginjurybypromotionofneutrophilapoptosisandinhibitionoftlr4myd88nfkbpathway
AT hanqianqian jinhuaqinggangranulesattenuatesacutelunginjurybypromotionofneutrophilapoptosisandinhibitionoftlr4myd88nfkbpathway
AT wanglei jinhuaqinggangranulesattenuatesacutelunginjurybypromotionofneutrophilapoptosisandinhibitionoftlr4myd88nfkbpathway
AT wangbaiyan jinhuaqinggangranulesattenuatesacutelunginjurybypromotionofneutrophilapoptosisandinhibitionoftlr4myd88nfkbpathway
AT chenjianshuang jinhuaqinggangranulesattenuatesacutelunginjurybypromotionofneutrophilapoptosisandinhibitionoftlr4myd88nfkbpathway
AT caibangrong jinhuaqinggangranulesattenuatesacutelunginjurybypromotionofneutrophilapoptosisandinhibitionoftlr4myd88nfkbpathway
AT wucan jinhuaqinggangranulesattenuatesacutelunginjurybypromotionofneutrophilapoptosisandinhibitionoftlr4myd88nfkbpathway
AT zhuxiali jinhuaqinggangranulesattenuatesacutelunginjurybypromotionofneutrophilapoptosisandinhibitionoftlr4myd88nfkbpathway
AT liufugang jinhuaqinggangranulesattenuatesacutelunginjurybypromotionofneutrophilapoptosisandinhibitionoftlr4myd88nfkbpathway
AT handeen jinhuaqinggangranulesattenuatesacutelunginjurybypromotionofneutrophilapoptosisandinhibitionoftlr4myd88nfkbpathway
AT donghaoran jinhuaqinggangranulesattenuatesacutelunginjurybypromotionofneutrophilapoptosisandinhibitionoftlr4myd88nfkbpathway
AT jiayongyan jinhuaqinggangranulesattenuatesacutelunginjurybypromotionofneutrophilapoptosisandinhibitionoftlr4myd88nfkbpathway
AT liuyalin jinhuaqinggangranulesattenuatesacutelunginjurybypromotionofneutrophilapoptosisandinhibitionoftlr4myd88nfkbpathway